News
Swiss biotech start-up Baxiva AG will receive $3 million to develop a multivalent glycoconjugate vaccine that targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback